117 related articles for article (PubMed ID: 2369548)
61. Effects of chirality in 9-(2-hydroxy-3-nonyl)adenine upon deoxyribonucleic acid synthesis in herpes simplex virus-infected cells.
North TW; O'Connor L; Abushanab E; Panzica RP
Biochem Pharmacol; 1983 Dec; 32(23):3541-6. PubMed ID: 6316987
[TBL] [Abstract][Full Text] [Related]
62. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.
Kwok JB; Tattersall MH
Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463
[TBL] [Abstract][Full Text] [Related]
63. Rejection of bone marrow transplant and resistance of alloantigen reactive cells to in vivo deoxyadenosine in adenosine deaminase deficiency.
Cowan MJ; Shannon KM; Wara DW; Ammann AJ
Clin Immunol Immunopathol; 1988 Nov; 49(2):242-50. PubMed ID: 2971490
[TBL] [Abstract][Full Text] [Related]
64. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
[TBL] [Abstract][Full Text] [Related]
65. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
Johnson CE; Hughes K; Cory JG
Cancer Commun; 1991; 3(10-11):341-9. PubMed ID: 1760249
[TBL] [Abstract][Full Text] [Related]
66. Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblasts.
Fox RM; Tripp EH; Taylor IW
Mol Pharmacol; 1984 Sep; 26(2):388-94. PubMed ID: 6332978
[TBL] [Abstract][Full Text] [Related]
67. In vivo growth inhibition of L1210 leukemia by 4-amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A), a new inhibitor of S-adenosylmethionine decarboxylase.
Dorhout B; Te Velde RJ; Ferwerda H; Kingma AW; De Hoog E; Muskiet FA
Int J Cancer; 1995 Apr; 61(2):214-7. PubMed ID: 7705950
[TBL] [Abstract][Full Text] [Related]
68. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Góra-Tybor J; Robak T; Warzocha K; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
[TBL] [Abstract][Full Text] [Related]
69. Characterization of a cultured human T-cell line with genetically altered ribonucleotide reductase activity. Model for immunodeficiency.
Waddell D; Ullman B
J Biol Chem; 1983 Apr; 258(7):4226-31. PubMed ID: 6339493
[TBL] [Abstract][Full Text] [Related]
70. Effect of combinations of deoxyguanosine and 8-aminoguanosine with 2,3-dihydro-1H-imidazo[1,2-b]pyrazole on L1210 cell growth in culture.
Sato A; Bacon PE; Schneller SW; Cory JG
Biochem Pharmacol; 1984 Feb; 33(4):689-91. PubMed ID: 6704189
[No Abstract] [Full Text] [Related]
71. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine.
Porter DJ; Abushanab E
Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161
[TBL] [Abstract][Full Text] [Related]
72. Cytotoxic and metabolic effects of adenosine and adenine on human lymphoblasts.
Snyder FF; Hershfield MS; Seegmiller JE
Cancer Res; 1978 Aug; 38(8):2357-62. PubMed ID: 667833
[TBL] [Abstract][Full Text] [Related]
73. In vivo effects of 4-amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A) and alpha-difluoromethylornithine (DFMO) on L1210 growth, cell-cycle phase distribution and polyamine contents.
Dorhout B; te Velde RJ; Ferwerda H; Kingma AW; de Hoog E; Muskiet FA
Int J Cancer; 1995 Sep; 62(6):738-42. PubMed ID: 7558423
[TBL] [Abstract][Full Text] [Related]
74. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
75. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of the effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA) on HIV-1 production in vitro.
Sei Y; Inoue M; Tsuboi I; Yokoyama MM; Arora PK
Biochem Biophys Res Commun; 1989 Oct; 164(1):345-50. PubMed ID: 2478129
[TBL] [Abstract][Full Text] [Related]
77. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
Albert D; Bluestein HG; Thompson L; Seegmiller JE
Cell Immunol; 1984 Jul; 86(2):510-7. PubMed ID: 6610485
[TBL] [Abstract][Full Text] [Related]
78. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
79. Deoxyribonucleoside-triphosphate imbalance death: deoxyadenosine-induced dNTP imbalance and DNA double strand breaks in mouse FM3A cells and the mechanism of cell death.
Yoshioka A; Tanaka S; Hiraoka O; Koyama Y; Hirota Y; Wataya Y
Biochem Biophys Res Commun; 1987 Jul; 146(1):258-64. PubMed ID: 3496883
[TBL] [Abstract][Full Text] [Related]
80. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
